insights_auto
Prečo akcie TRVN klesli 99,24%?
Preskúmať podrobnejšiechevron_right
TRVN:OTCMKTS
Trevena Inc
0,00050 USD
arrow_downward
-99,24%(-0,066) 1 d.
16. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre TRVN…
Otvoriť
0,00 USD
Vysoká
0,00 USD
Nízka
0,00 USD
Trh. kap.
407,21
Priem. obj.
210,00
Objem
4,13 tis.
Max. za 52 týž.
1,50 USD
Min. za 52 týž.
0,00 USD
Beta
1,07
Akcie v obehu
864,00 tis.
Počet zamestnancov
23
Otvoriť
0,00 USD
Vysoká
0,00 USD
Nízka
0,00 USD
Trh. kap.
407,21
Priem. obj.
210,00
Objem
4,13 tis.
Max. za 52 týž.
1,50 USD
Min. za 52 týž.
0,00 USD
Beta
1,07
Akcie v obehu
864,00 tis.
Počet zamestnancov
23
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Yahoo Finance
·
pred 4 hodinami
Michael Burry Warns of a Stock Market ‘Supervolcano’
AOL.com
·
pred 33 minútami
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
Simply Wall Street
·
pred 1 hodinou
Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?
MarketWatch
·
pred 1 hodinou
Opinion: There is a silent market rotation inside the S&P 500 that’s warning of more weakness ahead
Profil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Informácie o subjekte Trevena Inc
Generálny riaditeľ-
Zamestnanci23
Dátum založenia2007
Hlavné sídloAtlanta, Georgia, Spojené štáty americké
Odvetvie-
Webtrevena.com